FDA Approves Wound Dressing for Battlefield, Trauma Settings

Share this content:
Xstat 30 is cleared for use in patients at high risk for immediate, life-threatening, and severe hemorrhagic shock and non-compressible junctional wounds.
Xstat 30 is cleared for use in patients at high risk for immediate, life-threatening, and severe hemorrhagic shock and non-compressible junctional wounds.

Officials with the Food and Drug Administration have cleared the use of the Xstat 30 (RevMedX) wound dressing, an expandable, multi-sponge dressing used to control severe, life-threatening bleeding from wounds in areas that a tourniquet cannot be placed (such as the groin or armpit) in battlefield and civilian trauma settings. The clearance expands the device's indication from use by the military only to use in adults and adolescents in the general population.  

Xstat 30 is cleared for use in patients at high risk for immediate, life-threatening, and severe hemorrhagic shock and non-compressible junctional wounds, when definitive care at an emergency care facility cannot be achieved within minutes. Xstat 30 is not indicated for use in certain parts of the chest, abdomen, pelvis or tissue above the collarbone. 

The dressing can be used for up to four hours, which could allow time for the patient to receive surgical care. The device is available in packages of one or three syringe-style applicators containing 92 compressed, cellulose sponges that have an absorbent coating. The sponges expand and swell to fill the wound cavity, creating a temporary physical barrier to blood flow. The number of sponges needed for effective hemorrhage control will vary, depending on the size and depth of the wound. Each applicator can absorb about a pint of blood, and up to three applicators may be used on a patient.  

You must be a registered member of Infectious Disease Advisor to post a comment.

Sign Up for Free e-newsletters